Australian VC firms back Spinifex Pharmaceuticals
GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest have participated in the Series B round of financing for Spinifex Pharmaceuticals. The Australian drug development company raised a total of $19 million, $6.5 million more than its original target.
The funds will be put toward phase-two clinical trials for Spinifex's pain management drug, EMA401. The trials will focus on using EMA401 to treat pain and hypersensitivity in peripheral nerve injury patients...
More on Australasia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.